Unravel Biosciences Receives FDA Orphan Drug Designation for Vorinostat (RVL-001) as a Treatment for Rett Syndrome

Initiation of global clinical development program for RVL-001 in Rett syndrome underway, with recently announced Rett studies in the US led by Vanderbilt and in Colombia led by Unravel. BOSTON, May 28, 2024 /PRNewswire/ — Unravel Biosciences, Inc., (“Unravel”), an AI-enabled therapeutics…